First-in-kind psychedelic trials treat opioid and methamphetamine use disorders

Three million people in the United States have had opioid use disorder, and another 1.5 million people have dealt with methamphetamine misuse within the last year alone.

But two new groundbreaking clinical trials out of the UW Transdisciplinary Center for Research in Psychoactive Substances (TCRPS), housed within the University of Wisconsin–Madison School of Pharmacy, aim to address these pressing issues with a promising psychoactive agent: psilocybin.

The drug has shown encouraging results for patients with depression and with tobacco and alcohol misuse. Now, a UW–Madison research team is investigating the use of psilocybin to aid in decreasing opioid and methamphetamine misuse.

Read full story at